home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

9.390 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation

April 03, 2025

Via AB Newswire

Topics Intellectual Property

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

April 03, 2025

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

April 03, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 15, 2025

Via ACCESS Newswire

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

February 14, 2025

Via ACCESS Newswire

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

December 12, 2024

Via ACCESSWIRE

11 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 03, 2025

Via Benzinga

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High ↗

April 03, 2025

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

Via Stocktwits

Topics Government

These stocks that are showing activity before the opening bell on Thursday. ↗

April 03, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

April 03, 2025

Via ACCESS Newswire

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

December 04, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 03, 2025

Via Benzinga

Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

April 03, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

April 02, 2025

The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

What's Going On With Aptevo Therapeutics Shares Friday? ↗

November 29, 2024

Aptevo stock is trading lower after the company announced a 1-for-37 reverse stock split.

Via Benzinga

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

November 07, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 02, 2025

Via Benzinga

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment ↗

March 20, 2025

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment nearing completion.

Via Benzinga

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

March 20, 2025

Via ACCESS Newswire

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

March 18, 2025

Via ACCESS Newswire

Aptevo to Participate in March Conferences

March 06, 2025

Via ACCESS Newswire

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

January 15, 2025

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

December 12, 2024

Via ACCESSWIRE

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

November 29, 2024

Via ACCESSWIRE

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

November 26, 2024

Via ACCESSWIRE

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

November 22, 2024

Via ACCESSWIRE

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

November 20, 2024

Via ACCESSWIRE

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

November 11, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 29, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com